Literature DB >> 22268087

Imaging characteristics of oligodendrogliomas that predict grade.

L Khalid1, M Carone, N Dumrongpisutikul, J Intrapiromkul, D Bonekamp, P B Barker, D M Yousem.   

Abstract

BACKGROUND AND
PURPOSE: Oligodendrogliomas are tumors that have variable WHO grades depending on anaplasia and astrocytic components and their treatment may differ accordingly. Our aim was to retrospectively evaluate imaging features of oligodendrogliomas that predict tumor grade.
MATERIALS AND METHODS: The imaging studies of 75 patients with oligodendrogliomas were retrospectively reviewed and compared with the histologic grade. The presence and degree of enhancement and calcification were evaluated subjectively. rCBV and ADC maps were measured. Logistic linear regression models were used to determine the relationship between imaging factors and tumor grade.
RESULTS: Thirty of 75 (40%) tumors enhanced, including 9 of 46 (19.6%) grade II and 21 of 29 (72.4%) grade III tumors (P < .001). Grade III tumors showed lower ADC values compared with grade II tumors (odds ratio of a tumor being grade III rather than grade II = 0.07; 95% CI, 0.02-0.25; P = .001). An optimal ADC cutoff of 925 10(-6) mm(2)/s was established, which yielded a specificity of 89.1%, sensitivity of 62.1%, and accuracy of 78.7%. There was no statistically significant association between tumor grade and the presence of calcification and perfusion values. Multivariable prediction rules were applied for ADC < 925 10(-6) mm(2)/s, the presence of enhancement, and the presence of calcification. If either ADC < 925 10(-6) mm(2)/s or enhancement was present, it yielded 93.1% sensitivity, 73.9% specificity, and 81.3% accuracy. The most accurate (82.2%) predictive rule was seen when either ADC < 925 10(-6) mm(2)/s or enhancement and calcification were present.
CONCLUSIONS: Models based on contrast enhancement, calcification, and ADC values can assist in predicting the grade of oligodendrogliomas and help direct biopsy sites, raise suspicion of sampling error, and predict prognosis.

Entities:  

Mesh:

Year:  2012        PMID: 22268087      PMCID: PMC3404805          DOI: 10.3174/ajnr.A2895

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  31 in total

1.  Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.

Authors:  Meng Law; Sarah Oh; Glyn Johnson; James S Babb; David Zagzag; John Golfinos; Patrick J Kelly
Journal:  Neurosurgery       Date:  2006-06       Impact factor: 4.654

2.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

3.  MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas.

Authors:  Antonio C M Maia; Suzana M F Malheiros; Antonio J da Rocha; Carlos J da Silva; Alberto A Gabbai; Fernando A P Ferraz; João N Stávale
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

4.  Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.

Authors:  M Vittoria Spampinato; J Keith Smith; Lester Kwock; Matthew Ewend; John D Grimme; Daniel L A Camacho; Mauricio Castillo
Journal:  AJR Am J Roentgenol       Date:  2007-01       Impact factor: 3.959

Review 5.  From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation.

Authors:  Kelly K Koeller; Elisabeth J Rushing
Journal:  Radiographics       Date:  2005 Nov-Dec       Impact factor: 5.333

6.  Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study.

Authors:  C Chaskis; T Stadnik; A Michotte; K Van Rompaey; J D'Haens
Journal:  Acta Neurochir (Wien)       Date:  2006-01-19       Impact factor: 2.216

7.  Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors.

Authors:  Maosheng Xu; Siew Ju See; Wai Hoe Ng; Earnest Arul; Michael F Back; Tseng Tsai Yeo; C C Tchoyoson Lim
Journal:  Neurosurgery       Date:  2005-05       Impact factor: 4.654

8.  Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging.

Authors:  Robert G Whitmore; Jaroslaw Krejza; Gurpreet S Kapoor; Jason Huse; John H Woo; Stephanie Bloom; Joanna Lopinto; Ronald L Wolf; Kevin Judy; Myrna R Rosenfeld; Jaclyn A Biegel; Elias R Melhem; Donald M O'Rourke
Journal:  J Neurosurg       Date:  2007-09       Impact factor: 5.115

9.  Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001.

Authors:  Elizabeth B Claus; Peter M Black
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  15 in total

Review 1.  Hemorrhagic and non-hemorrhagic causes of signal loss on susceptibility-weighted imaging.

Authors:  Kamila A Skalski; Alexander T Kessler; Alok A Bhatt
Journal:  Emerg Radiol       Date:  2018-08-22

2.  Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival.

Authors:  Valeria Cuccarini; A Erbetta; M Farinotti; L Cuppini; F Ghielmetti; B Pollo; F Di Meco; M Grisoli; G Filippini; G Finocchiaro; M G Bruzzone; M Eoli
Journal:  J Neurooncol       Date:  2016-01       Impact factor: 4.130

3.  Grading of oligodendroglial tumors of the brain with apparent diffusion coefficient, magnetic resonance spectroscopy, and dynamic susceptibility contrast imaging.

Authors:  Muhammad Atif Naveed; Pradeep Goyal; Ajay Malhotra; Xiang Liu; Sonali Gupta; Manisha Mangla; Rajiv Mangla
Journal:  Neuroradiol J       Date:  2018-02-22

Review 4.  Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective.

Authors:  Preantha Poonan; Clement Agoni; Mahmoud A A Ibrahim; Mahmoud E S Soliman
Journal:  Protein J       Date:  2021-09-29       Impact factor: 2.371

5.  Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases.

Authors:  W L Tan; W Y Huang; B Yin; J Xiong; J S Wu; D Y Geng
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-20       Impact factor: 3.825

Review 6.  Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.

Authors:  Fred H Hochberg; Nadia A Atai; David Gonda; Michael S Hughes; Brolin Mawejje; Leonora Balaj; Robert S Carter
Journal:  Expert Rev Mol Diagn       Date:  2014-05       Impact factor: 5.225

7.  Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.

Authors:  Thomas Hundsberger; Michaela Tonder; Andreas Hottinger; Detlef Brügge; Ulrich Roelcke; Paul Martin Putora; Roger Stupp; Michael Weller
Journal:  J Neurooncol       Date:  2014-04-16       Impact factor: 4.130

8.  Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas.

Authors:  Julio Arevalo-Perez; Amanuel A Kebede; Kyung K Peck; Eli Diamond; Andrei I Holodny; Marc Rosenblum; Jennifer Rubel; Joshua Gaal; Vaios Hatzoglou
Journal:  J Neuroimaging       Date:  2015-12-26       Impact factor: 2.486

9.  Discrimination between glioma grades II and III in suspected low-grade gliomas using dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach.

Authors:  Anna Falk; Markus Fahlström; Egill Rostrup; Shala Berntsson; Maria Zetterling; Arvid Morell; Henrik B W Larsson; Anja Smits; Elna-Marie Larsson
Journal:  Neuroradiology       Date:  2014-09-10       Impact factor: 2.804

10.  Clinical features, diagnosis, and survival analysis of dogs with glioma.

Authors:  Roberto José-López; Rodrigo Gutierrez-Quintana; Cristian de la Fuente; Edgar G Manzanilla; Anna Suñol; Dolors Pi Castro; Sonia Añor; Daniel Sánchez-Masian; Francisco Fernández-Flores; Emanuele Ricci; Katia Marioni-Henry; Joan Mascort; Lara A Matiasek; Kaspar Matiasek; Paul M Brennan; Martí Pumarola
Journal:  J Vet Intern Med       Date:  2021-06-12       Impact factor: 3.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.